Skip Navigation Links
(B-43) A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy
Overall Recruitment Status: Enrollment complete
 
Official Title
(B-43) A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy
 
Region Sponsors
Colorado
National Cancer Institute (NCI)
 
Acronym NCT No.
NCT00769379
 
Study Type Phase
Clinical Trial
Phase III
 
Purpose
This randomized phase III trial studies radiation therapy to see how well it works with or without trastuzumab in treating women with ductal carcinoma in situ who have undergone lumpectomy. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Radiation therapy uses high-energy x-rays to kill tumor cells. It is not yet known whether radiation therapy is more effective with or without trastuzumab in treating ductal carcinoma in situ.
 
Detailed Description
 
 
 
Inclusion Criteria
  • The patient must have consented to participate and must have signed and dated an appropriate Institutional Review Board (IRB)-approved consent form that conforms to federal and institutional guidelines for the study treatment and for the pre-entry tumor block submission for HER2 testing and B-43 correlative studies
  • Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (0 = fully active, able to carry on all pre-disease performance without restriction
  • 1 = restricted in physically strenuous activity but ambulatory)
  • On histologic examination, the tumor must be ductal carcinoma in situ (DCIS) (patients with mixed DCIS and lobular carcinoma in situ [LCIS] are eligible)
  • The DCIS must be HER2-positive as determined by central testing
  • Estrogen and/or progesterone receptor status must be determined prior to randomization (patients with DCIS that is hormone receptor positive or negative are eligible)
 
Exclusion Criteria
  • Invasive (including microinvasion staged as T1mic) breast cancer (patients with DCIS "suspicious" for microinvasion, but not confirmed, are eligible)
  • Nodal staging of pN1 (including pN1mi) (note: axillary staging is not required)
  • DCIS present in more than one quadrant (multicentric)
  • Masses or clusters of calcification that are clinically or mammographically suspicious unless biopsied and proven to be benign (if DCIS is found, the patient is eligible if the DCIS was in the same quadrant of the ipsilateral breast and was resected with clear margins)
  • Contralateral breast cancer (including DCIS)
 
Keywords and/or Specific Medical Conditions
  • Obstetrics and Gynecology
  • Oncology (Adult)
 
KP Clinical Facility
  • Lone Tree Medical Offices - Lone Tree
 
Clinical Area
  • Obstetrics and Gynecology
  • Oncology (Adult)


Principal Investigator:
Alex Menter
Contact Information:
- CTP Team
-ctpcollaborate@kp.org
-Lone Tree Medical Offices - Lone Tree


smilelady1
Do you want to receive
Email Alerts?
Sign Up Here!